R
Ronald M. Paranal
Researcher at Harvard University
Publications - 19
Citations - 5508
Ronald M. Paranal is an academic researcher from Harvard University. The author has contributed to research in topics: Bromodomain & Histone deacetylase. The author has an hindex of 13, co-authored 19 publications receiving 4727 citations. Previous affiliations of Ronald M. Paranal include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
Journal ArticleDOI
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Charles Y. Lin,Jakob Lovén,Peter B. Rahl,Ronald M. Paranal,Christopher B. Burge,James E. Bradner,Tong Ihn Lee,Richard A. Young +7 more
TL;DR: It is reported here that in tumor cells expressing high levels of c-Myc the transcription factor accumulates in the promoter regions of active genes and causes transcriptional amplification, producing increased levels of transcripts within the cell's gene expression program.
Journal ArticleDOI
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Jonathan D. Brown,Charles Y. Lin,Qiong Duan,Qiong Duan,Gabriel K. Griffin,Alexander J. Federation,Ronald M. Paranal,Steven M. Bair,Gail Newton,Andrew H. Lichtman,Andrew L. Kung,Andrew L. Kung,Tianlun Yang,Hong Wang,Francis W. Luscinskas,Kevin Croce,James E. Bradner,Jorge Plutzky +17 more
TL;DR: A chemical genetic approach reveals a requirement for BET bromodomains in communicating enhancer remodeling to RNA Polymerase II and orchestrating the transition to the inflammatory cell state, demonstrated in activated endothelium and macrophages.
Journal ArticleDOI
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott,Nadja Kopp,Liat Bird,Ronald M. Paranal,Jun Qi,Teresa V. Bowman,Teresa V. Bowman,Scott J. Rodig,Scott J. Rodig,Andrew L. Kung,James E. Bradner,David M. Weinstock +11 more
TL;DR: In mice xenografted with primary human CRLF2-rearranged B-ALL, JQ1 suppressed c-Myc expression and STAT5 phosphorylation and significantly prolonged survival and bromodomain inhibition is a promising therapeutic strategy for B-all as well as other conditions dependent on IL7R signaling.
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc.